Connor, Clark & Lunn Investment Management Ltd. Syros Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $22 Billion
  • Q2 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022
SELL
$0.69 - $1.21 $83,276 - $146,034
-120,690 Reduced 87.99%
16,466 $16,000
Q1 2022

May 12, 2022
BUY
$1.02 - $3.8 $18,894 - $70,391
18,524 Added 15.61%
137,156 $163,000
Q4 2021

Feb 10, 2022
BUY
$3.26 - $4.66 $49,959 - $71,414
15,325 Added 14.83%
118,632 $387,000
Q3 2021

Nov 12, 2021
BUY
$4.08 - $5.66 $111,200 - $154,263
27,255 Added 35.84%
103,307 $462,000
Q2 2021

Aug 12, 2021
BUY
$5.01 - $7.48 $381,020 - $568,868
76,052 New
76,052 $414,000
Q3 2019

Nov 13, 2019
SELL
$7.14 - $11.65 $205,903 - $335,962
-28,838 Closed
0 $0
Q2 2019

Aug 07, 2019
SELL
$5.5 - $9.75 $495,126 - $877,724
-90,023 Reduced 75.74%
28,838 $267,000
Q1 2019

May 08, 2019
SELL
$5.51 - $9.59 $20,387 - $35,483
-3,700 Reduced 3.02%
118,861 $1.09 Million
Q4 2018

Feb 12, 2019
BUY
$5.55 - $11.34 $21,645 - $44,226
3,900 Added 3.29%
122,561 $683,000
Q3 2018

Nov 13, 2018
BUY
$9.74 - $12.92 $155,840 - $206,720
16,000 Added 15.59%
118,661 $1.41 Million
Q2 2018

Aug 02, 2018
BUY
$10.16 - $13.65 $460,756 - $619,027
45,350 Added 79.13%
102,661 $1.05 Million
Q1 2018

May 14, 2018
BUY
$9.47 - $12.98 $404,369 - $554,246
42,700 Added 292.25%
57,311 $744,000
Q4 2017

Feb 09, 2018
BUY
$8.45 - $17.48 $123,462 - $255,400
14,611
14,611 $142,000

About Syros Pharmaceuticals, Inc.

SYRS Quotes by TradingView
  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email